Compared with the basic treatment group , a lower proportion of patients in the DCXC treatment groups had an eGFR decrease of 25 % or greater ( P < 0.05 ) ; patients with an eGFR decrease of 25 % or greater accounted for an even lower proportion in the intensive DCXC therapy group ( P < 0.01 ) .